Gilead Sciences’ ($GILD) hep C drug Sovaldi burst onto the market, impressing doctors and patients with its benefits and outraging payers and politicians with its price. It reached blockbuster status twice over in the course of a single quarter. But instead of an aberration, a new report suggests it is a reflection of a trend that has […]
Always Be a Step Ahead
Learn the important healthcare trends that could affect you in advance. Get expert analysis and discover the innovative ideas that are helping businesses overcome today's challenges.
Subscribe to AMI's Insights Newsletter Today.